Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Vaccine technique shows potential against common form of lung cancer

14.02.2003


In a demonstration of vaccine therapy’s potential for treating lung cancer, Dana-Farber Cancer Institute scientists and their associates report that a prototype vaccine boosted the natural immune response to tumors in a small group of patients with advanced non-small cell lung cancer (NSCLC). Moreover, the vaccine was found to be non-toxic and well-tolerated.



Published in the Feb. 15 issue of the Journal of Clinical Oncology, findings from the Phase I clinical trial will provide an impetus for further efforts to develop a vaccine against NSCLC, a difficult-to-treat condition that accounts for roughly 80 percent of all lung cancer cases. (Phase I trials are designed primarily to assess the safety of an experimental treatment.)

"This work represents a new approach to a vaccine for lung cancer patients,” says senior author Glenn Dranoff, MD, of Dana-Farber. "We’re still at an early stage, but the results of this study are encouraging. They offer a ’proof of principle’ that this technique can strengthen the normal immune response to NSCLC tumors and will help form the basis for testing the vaccine in patients with earlier stage lung cancer."


The technique was originally developed for patients with advanced melanoma, a form of cancer that begins in the skin but can be deadly if allowed to spread to other parts of the body.

The researchers created the melanoma vaccine by removing a portion of a patient’s tumor and using specially equipped viruses to insert a gene known as GM-CSF into the tumor cells. After being radiated and injected into the patient, the manipulated tumor cells began producing the granulocyte-macrophage colony-stimulating factor (GM-CSF) protein, which acted as a magnet for an immune system attack on tumor cells. As the researchers had hoped, the vaccine elicited a potent, long-lasting immune response targeted at the melanoma tumor cells and produced only minor side effects.

In the lung cancer study, researchers developed vaccines for 34 of the 35 enrolled patients with metastatic, or spreading, NSCLC. Nine of these patients had to withdraw from the study after their disease progressed rapidly, but researchers found heightened levels of immune-system cells in 18 of 25 patients whose condition could be assessed after vaccination. Tumor samples removed after vaccination showed infiltration by immune-system cells and tumor-cell death in three of six patients. Side effects were minor, mostly involving irritation at the site of the vaccine injection.

Two patients, the removal of whose tumors for vaccine preparation left them with no evidence of the disease, remained disease-free more than three years after vaccination. Five patients had periods of stable disease ranging from three to 33 months.

"The results demonstrate that the technique can raise antitumor immunity in some patients with NSCLC," states Dranoff, who is also an associate professor of medicine at Harvard Medical School. "It is important to keep these findings in proper perspective: they are promising but still preliminary. More research needs to be done to see if these results occur in larger studies and in people with earlier stages of NSCLC."

Ravi Salgia, MD, PhD, of Dana-Farber, and Thomas Lynch, MD, of Massachusetts General Hospital, were first authors of the paper. Other contributors are based at Dana-Farber, Children’s Hospital Boston, Massachusetts General Hospital, and Cell Genesys of Foster City, Calif.



Funding for the study was provided by the National Institutes of Health, the Cancer Research Institute, the Leukemia and Lymphoma Society, and Cell Genesys.

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Bill Schaller | EurekAlert!
Further information:
http://www.dfci.harvard.edu/

More articles from Health and Medicine:

nachricht Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University

nachricht Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

What the world's tiniest 'monster truck' reveals

23.08.2017 | Life Sciences

Treating arthritis with algae

23.08.2017 | Life Sciences

Witnessing turbulent motion in the atmosphere of a distant star

23.08.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>